Adaptimmune is a clinical-stage company with multiple ongoing clinical trials in oncology (see Clinical Trials tab).  Data from some of these studies have been publicly presented (see News & Events tab). Adaptimmune is a fully independent biotechnology company with a robust product pipeline, a clear intellectual property position, and an effective and scalable clinical capacity capable of supporting both pilot and pivotal studies.

Adaptimmune is interested in talking to potential partners capable of making a significant commitment to late stage development and commercialization of T cell therapies.

For further information, please contact: